ArticleJournal of nanobiotechnology2025
Aptamer-engineered NIR-II Ru-doped carbon quantum dot nanozyme for photoacoustic imaging-guided synergistic photothermal and catalytic cancer therapy.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Tetrahedral DNA nano-PROTACs enable enhanced ocular penetration and efficient nucleolin degradation for choroidal neovascularization therapy.Signal transduction and targeted therapy · 2026Article
- A hemoglobin-based nanozyme with ruthenium-induced nanomotor ability exhibiting photothermal and chemodynamic responses.Mikrochimica acta · 2026Article
- Global research trends and emerging frontiers of nanozymes in cancer therapy based on bibliometric and knowledge mapping analysis from 2001 to 2025.Discover nano · 2026Review
- DNA Nanotechnology-Enabled Precise Regulation of Nanozymes and Their Applications.Research (Washington, D.C.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Carbon quantum dot (CQD)-based nanozymes have attracted growing interest for advanced biomedical applications owing to their superior catalytic activity, photostability, and biocompatibility. However, the rational design of a multifunctional nanoplatform that integrates active targeting, multimodal imaging, and synergistic therapy through a green and sustainable approach remains highly challenging. Herein, we report a facile and environmentally benign solvothermal strategy for the synthesis of ruthenium-doped CQD nanozymes (Ru-CQDs) functionalized with AS1411 aptamers and polyethylene glycol (PEG), denoted as Ru-CQDs-AS1411@PEG. This eco-friendly synthesis avoids toxic reagents and harsh conditions while yielding highly uniform and biocompatible nanozymes. The obtained Ru-CQDs-AS1411@PEG exhibit strong NIR-II absorption, high photothermal conversion efficiency, and pronounced peroxidase-mimicking catalytic activity. The AS1411 aptamer confers active tumor-targeting capability, while PEGylation enhances aqueous dispersibility and physiological stability. Both in vitro and in vivo studies demonstrate that Ru-CQDs-AS1411@PEG enable precise photoacoustic tumor imaging and potent tumor ablation under NIR-II laser irradiation via synergistic photothermal and catalytic reactive oxygen species (ROS) generation. This work provides a green-engineered, aptamer-guided CQD nanozyme platform with integrated targeting, imaging, and therapeutic functionalities, offering a promising and sustainable approach for precision cancer theranostics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.